67 Views | 44 Downloads
Correspondence: cdnwagw@emory.edu
Author contributions: Conceptualization, C.D.N. and A.-M.C.; methodology, C.D.N., A.V.I., M.Y.J., D.C.A.; validation, A.-M.C. and D.C.A.; investigation, C.D.N., A.V.I., M.Y.J. and O.A.; data curation, C.D.N. and A.V.I.; writing—original draft preparation, C.D.N., A.V.I., M.Y.J. and O.A.; writing—review and editing, D.C.A.; visualization, C.D.N. All authors have read and agreed to the published version of the manuscript.
Disclosures: Anne-Marie Carbonell is the President and CEO of OncoSynergy, Inc. (manufacturer of OS2966) and holds an equity interest in the company. The rest of the authors declare no conflict of interest.
This research received no external funding.
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.